IBDEI0NC ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11484,1,2,0)
 ;;=2^OTHER INTESTINAL COND
 ;;^UTILITY(U,$J,358.3,11484,2)
 ;;=^123842
 ;;^UTILITY(U,$J,358.3,11485,0)
 ;;=573.9^^76^752^21
 ;;^UTILITY(U,$J,358.3,11485,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11485,1,1,0)
 ;;=1^573.9
 ;;^UTILITY(U,$J,358.3,11485,1,2,0)
 ;;=2^OTHER LIVER DISEASE
 ;;^UTILITY(U,$J,358.3,11485,2)
 ;;=^123854
 ;;^UTILITY(U,$J,358.3,11486,0)
 ;;=580.9^^76^753^1
 ;;^UTILITY(U,$J,358.3,11486,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11486,1,1,0)
 ;;=1^580.9
 ;;^UTILITY(U,$J,358.3,11486,1,2,0)
 ;;=2^ACUTE GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,11486,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,11487,0)
 ;;=584.9^^76^753^2
 ;;^UTILITY(U,$J,358.3,11487,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11487,1,1,0)
 ;;=1^584.9
 ;;^UTILITY(U,$J,358.3,11487,1,2,0)
 ;;=2^ACUTE RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,11487,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,11488,0)
 ;;=582.9^^76^753^3
 ;;^UTILITY(U,$J,358.3,11488,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11488,1,1,0)
 ;;=1^582.9
 ;;^UTILITY(U,$J,358.3,11488,1,2,0)
 ;;=2^CHRONIC GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,11488,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,11489,0)
 ;;=585.9^^76^753^4
 ;;^UTILITY(U,$J,358.3,11489,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11489,1,1,0)
 ;;=1^585.9
 ;;^UTILITY(U,$J,358.3,11489,1,2,0)
 ;;=2^CHRONIC KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,11489,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,11490,0)
 ;;=586.^^76^753^5
 ;;^UTILITY(U,$J,358.3,11490,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11490,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,11490,1,2,0)
 ;;=2^OTHER RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,11490,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,11491,0)
 ;;=694.9^^76^754^1
 ;;^UTILITY(U,$J,358.3,11491,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11491,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,11491,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,11491,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,11492,0)
 ;;=695.10^^76^754^2
 ;;^UTILITY(U,$J,358.3,11492,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11492,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,11492,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,11492,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,11493,0)
 ;;=696.1^^76^754^3
 ;;^UTILITY(U,$J,358.3,11493,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11493,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,11493,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,11493,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,11494,0)
 ;;=695.81^^76^754^4
 ;;^UTILITY(U,$J,358.3,11494,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11494,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,11494,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,11494,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,11495,0)
 ;;=695.13^^76^754^5
 ;;^UTILITY(U,$J,358.3,11495,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11495,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,11495,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,11495,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,11496,0)
 ;;=695.15^^76^754^6
 ;;^UTILITY(U,$J,358.3,11496,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11496,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,11496,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,11496,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,11497,0)
 ;;=695.9^^76^754^7
 ;;^UTILITY(U,$J,358.3,11497,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11497,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,11497,1,2,0)
 ;;=2^OTHER ERYTHEMATOUS SKIN COND
 ;;^UTILITY(U,$J,358.3,11497,2)
 ;;=^123902
 ;;^UTILITY(U,$J,358.3,11498,0)
 ;;=441.9^^76^755^2
 ;;^UTILITY(U,$J,358.3,11498,1,0)
 ;;=^358.31IA^2^2
